Could HEXO Corp. (TSX:HEXO) or Cronos Group Inc. (TSX:CRON) Be the Next Weed Stock Takeover Target?

HEXO Corp. (TSX:HEXO) and Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) might be candidates in the next round of cannabis stock takeovers. Is one more attractive?

| More on:

Consolidation has been the name of the game in 2018 for Canadian cannabis stocks.

Lets take a look at HEXO (TSX:HEXO) and Cronos Group (TSX:CRON)(NASDAQ:CRON) to see if one might be an attractive buy for the larger players in the marijuana stock sector.

HEXO

Quebec-based HEXO’s corporate headquarters isn’t too far from industry leader Canopy Growth. In fact, the trip from Gatineau to Smiths Falls is a mere 80 km and only takes about an hour, depending on traffic.

The close proximity of the offices and production sites might appear to make a tie-up appealing, but Canopy Growth’s CEO has said he is more interested in international acquisition opportunities than in additional Canadian ones. That might be the case, given the company’s existing strong presence in the Canadian market. Canopy Growth was an early mover in the consolidation game, buying up key competitors when prices were cheaper than they are today.

Another reason Canopy Growth might not be interested in HEXO is the potential conflict on the drinks side. Canopy Growth is 38% owned by Corona-maker Constellation Brands. HEXO has an agreement with Molson Coors Canada to set up a joint venture to develop cannabis-infused beverages.

A more likely suitor could be Aurora Cannabis. The company has already made two large acquisitions in the Canadian marijuana sector this year, spending $1.1 billion for CanniMed and $2.5 billion for MedReleaf. To date, Aurora Cannabis doesn’t have a dance partner in the beverage industry, so a takeover of HEXO would quickly sort that out, and Molson Coors would be an appealing choice.

Aurora Cannabis isn’t afraid to do big deals, so HEXO’s current market capitalization of $1.6 billion shouldn’t scare it off. At the time of writing, Aurora Cannabis has a market capitalization of $11.3 billion.

Cronos Group

Cronos Group is playing catch-up in Canada and is expanding its presence in Europe, Australia, Israel, and Latin America.

The European and Latin American markets are home to more than 1.1 billion people, so the appeal in these regions for long-term growth opportunities could entice one of the larger players to scoop up Cronos while it is getting established.

Cronos has another interesting side to the business that could make it attractive. The company has partnered with Ginko Bioworks to conduct research that would remove the key cannabinoids from the plants and reproduce them in a lab environment. The potential uses are extensive in the wellness industry, and in fragrance, cosmetic, and consumable applications. If a company can succeed in eliminating the need to spend billions on greenhouses to grow plants, it would completely disrupt the industry.

Canopy Growth gets a lot of media attention for its planned forays into the recreational market and cannabis culture brands, but the health side of the industry is very important to the company, so Cronos might be an interesting target.

At the time of writing, Cronos has a market capitalization of $2.4 billion.

Should you bet on a buyout?

HEXO and Cronos are both trading at very expensive levels after the rallies that occurred in the past two months. As such, investors should be cautious when starting a new position.

Eventually, I suspect the two companies will be bought, but when that will happen and at what price is anyone’s guess. If you want to make a speculative investment, I think HEXO might be the first to go, but I would wait for a better entry point.

Other potential home run opportunities exist in the market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned. The Motley Fool owns shares of Molson Coors Brewing.

More on Investing

Paper Canadian currency of various denominations
Dividend Stocks

2 Top Canadian Dividend Stocks to Buy on a Pullback

These stocks deserve to be on your radar today.

Read more »

ways to boost income
Dividend Stocks

This 10.18% Dividend Stock Is My Pick for Immediate Income

This dividend stock offers an impressive dividend yield, but is that enough for investors to consider long term?

Read more »

a sign flashes global stock data
Investing

Should You Buy Dentalcorp Holding While it’s Below $10?

Investors who prefer to stick to blue-chip stocks may have reservations about trading with a single-digit price tag, but these…

Read more »

Pile of Canadian dollar bills in various denominations
Investing

Here’s Where I’m Investing My Next $2,500 on the TSX

Here's why Restaurant Brands (TSX:QSR) remains one of my top picks in the market right now.

Read more »

Confused person shrugging
Dividend Stocks

Telus: Buy, Sell, or Hold in 2025?

Telus is down 20% in the past year. Is the stock now undervalued?

Read more »

Dividend Stocks

The CRA Is Watching: The Least-Known TFSA Red Flags

If you want to keep your TFSA growing, don't get the CRA on your back. Avoid these pitfalls, and invest…

Read more »

Train cars pass over trestle bridge in the mountains
Stock Market

Where Will Canadian Pacific Kansas City Stock Be in 3 Years?

Down 13% from all-time highs, Canadian Pacific Kansas City trades at reasonable valuation and should beat the TSX index in…

Read more »

An investor uses a tablet
Dividend Stocks

BCE Stock: A Lukewarm Outlook for 2025

BCE Inc (TSX:BCE) stock has a tepid outlook for 2025.

Read more »